Esophagogastric junctional adenocarcinoma
Conditions
Interventions
Conventional Laparoscopy Surgery Group:Conventional multi-port laparoscopic total gastrectomy, esophageal-jejunostomy, and D2 lymph node dissection
Single-incision plus one-port Laparoscopic Surgery:Single-incision plus one-port laparoscopic total gastrectomy, esophageal-jejunostomy, D2 lymph node dissection
Sponsors
Affiliated Hospital of North Sichuan Medical College
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: A. Aged 18-85 years; B. Pathological diagnosis of the primary lesion as adenocarcinoma (e.g., papillary adenocarcinoma, tubular adenocarcinoma, mucinous adenocarcinoma, signet ring cell carcinoma, mixed adenocarcinoma, etc.); C. Confirmed by gastroscopy as Siewert type II or III adenocarcinoma of the esophagogastric junction, with preoperative imaging assessment indicating the possibility of radical resection; D. Preoperative ASA (American Society of Anesthesiologists) score: I-III; E. Clinical stage: T1-4aN0-3M0 (based on the AJCC 8th Edition Cancer Staging Manual, regardless of whether preoperative neoadjuvant therapy was administered); F. BMI (Body Mass Index) < 30 kg/m^2; G. The patient has provided written informed consent.
Exclusion criteria
Exclusion criteria: A. Previous gastrointestinal surgery; B. Gastric cancer complications (bleeding, perforation, obstruction) requiring emergency surgery; C. Multiple malignant diseases; D. Women who are pregnant or breastfeeding; E. Severe mental illness; F. Severe liver or kidney dysfunction, coagulation disorders, or significant comorbidities that render the patient unable to tolerate surgery; G. Preoperative body temperature >= 38°C or presence of infectious diseases requiring systemic treatment; H. Severe respiratory diseases; I. Unstable angina or a history of myocardial infarction within the past 6 months; J. History of cerebral infarction or cerebral hemorrhage within the past 6 months; K. Continuous systemic corticosteroid therapy within the past month (excluding topical use); L. History of major upper abdominal surgery (excluding laparoscopic cholecystectomy); M. The patient is currently participating or has participated in other clinical trials within the past 6 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 3-year disease-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Perioperative complication rate;Surgical quality ;3-year overall survival; | — |
Countries
China
Contacts
Public ContactShoujiang Wei
Affiliated Hospital of North Sichuan Medical College
Outcome results
None listed